한글목차

개요

능동형 이식형 의료기기는 진단 또는 치료 목적으로 인체에 전체 또는 부분적으로 삽입하는 것을 목적으로 하는 능동형 의료기기를 말합니다. 능동형 이식형 의료기기에는 심박조율기, 제세동기, 수액펌프, 심실보조장치(VAD), 인공와우, 신경자극기 등 다양한 기기가 포함됩니다.

능동형 이식형 의료기기는 장기간 신체에 직접 접촉하도록 설계되었으며, 환자의 건강과 안전을 보호하기 위해 엄격한 기준과 요구사항이 부과됩니다. 또한 능동형 이식형 의료기기는 심혈관, 신경학, 정형외과 등 다양한 분야에서 널리 사용되고 있습니다.

시장 역학

장비 출시 증가

능동형 이식형 의료기기의 제품 출시가 증가하는 것은 시장 성장의 중요한 원동력이 되고 있습니다. 또한 많은 주요 기업들이 새로운 치료 장치를 출시하여 시장 발전에 큰 역할을 하고 있습니다.

예를 들어, 2023년 5월, MicroPort CRM은 최신 이식형 심박조율기 시리즈인 AlizeaTM와 CeleaTM의 미국 FDA 승인을 획득했습니다. 이들은 최신 심박조율기 기술로 크기가 작고 피하에 눈에 잘 띄지 않아 쉽게 이식할 수 있습니다.

또한, 메드트로닉은 2022년 12월 파킨슨병 등 신경질환 환자에게 전기적 뇌심부자극(DBS) 치료를 제공하는 브레인센스(BrainSense) 기술을 탑재한 뇌심부자극기 퍼셉트PC를 출시했습니다.

또한 2022년 8월, 메드트로닉(Medtronic plc.)은 흉골 아래에 리드를 삽입하는 혈관외 삽입형 제세동기(EV ICD) 시스템 제세동기를 출시하였습니다.

또한, 만성질환의 유병률 및 발병률 증가, 능동형 이식형 의료기기의 사용으로 인한 최소침습수술의 채택 확대 등 중요한 성장 촉진요인이 예측 기간 동안 시장을 견인할 것으로 예상됩니다.

심장박동기와 관련된 합병증

Mayo Clinic에 따르면, 이식형 심박조율기와 관련된 합병증은 예측 기간 동안 시장 성장을 저해할 것으로 보이며, 특히 환자가 혈액 희석제를 복용하는 경우 심박조율기 부위에 부종, 출혈, 타박상을 유발할 수 있다고 합니다. 또한, 심박조율기 부위에 혈전색전증(혈액 덩어리)이나 심박조율기 주변의 혈관 및 신경 손상을 유발할 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• DMI의 견해

제6장 COVID-19 분석

제7장 디바이스 유형별

• 삽입형 제세동기
  • 경정맥 삽입형 제세동기
    • 양심실 삽입형 제세동기
    • 듀얼 챔버 삽입형 제세동기
    • 싱글 챔버 삽입형 제세동기
  • 피하 삽입형 제세동기
• 삽입형 심장 페이스메이커
• 보조 인공 심장
• 신경 자극 기기
• 삽입형 보청기
• 삽입형 심장 모니터
• 삽입형 글루코오스 모니터

제8장 용도별

• 심장혈관
• 신경
• 정형외과
• 기타

제9장 최종사용자별

• 병원
• 외래수술센터(ASC)
• 심장 센터
• 신경센터
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• M&A분석

제12장 기업 개요

• Boston Scientific Corporation
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Medtronic Plc
• MED-EL
• Nurotron Biotechnology Co. Ltd.
• Abbott Laboratories
• Cochlear Ltd
• Sanova Holding AG
• LivaNova Plc
• Biotronik Inc.
• Osypka Medical

제13장 부록

영문목차

Overview

An active implantable medical device is an active medical device intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes. An active implantable medical device includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

Active implantable medical devices are designed to remain in direct contact with the body for extended periods and they are subject to rigorous standards and requirements to protect the health and safety of patients. Active implantable medical devices are also widely used in various applications such as in the cardiovascular, neurology, and orthopedic.

Market Dynamics

Increasing device launches

The increasing number of product launches for active implantable medical devices acts as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new treatment devices.

For instance, in May 2023, MicroPort CRM received U.S. FDA approval for its latest range of implantable pacemakers, AlizeaTM and CeleaTM. These are modern pacemaker technology that is small and discrete under the skin, making it easier to implant.

Also, in December 2022, Medtronic launched a deep brain implantable stimulator called Percept PC which is equipped with technology called BrainSense to provide electrical deep brain stimulation (DBS) treatment to patients with neurological diseases such as Parkinson's disease.

Additionally, in August 2022, Medtronic plc. Launched an extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with a lead put under the breastbone.

Furthermore, significant growth drivers such as the rising prevalence and incidence of chronic diseases, and the growing adoption of minimally invasive surgeries by using active implantable medical devices are expected to drive the market in the forecast period.

Complications related to implantable pacemakers

The complications related to implanted pacemakers will hamper the market growth in the forecast period. As per the Mayo Clinic, swelling, bleeding, or bruising can occur at the pacemaker site, particularly if the patient is taking blood thinners. It can also cause thromboembolism (blood clots) near the pacemaker site or the blood vessel or nerve damage near the pacemaker.

Segment Analysis

The global active implantable medical devices market is segmented based on device type, application, end users, and region.

Neurostimulators accounted for approximately 47.3% of the market share

An implantable neurostimulator delivers mild electrical signals to the epidural space near the spine through thin wires called leads. Neurostimulators are expected to hold the largest market share over the period forecast owing to increasing new neurostimulator launches and technical advancements.

For instance, in April 2023, Synapse Biomedical, Inc. launched the NeuRx Diaphragm Pacing System which is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy.

Additionally, in December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system which is the smallest implantable, rechargeable spinal cord stimulator for the treatment of chronic pain.

Geographical Analysis

North America is expected to hold a significant position in the global active implantable medical devices market share

The global active implantable medical devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of atrial fibrillation, and increasing adoption of cardiac pacemaker implantation, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health 2022, it is estimated that in the United States, the number of people with an implantable pacemaker is between 500,000 and 3 million. The chance of pacemaker implantation increases with age for over 70% of all pacemakers that are implanted in patients over the age of 65.

Additionally, according to Healthline Media, it is estimated that the prevalence of atrial fibrillation in the United States ranges from about 2.7 million to 6.1 million. It is estimated to rise to 12.1 million in 2030. Hence, due to the increasing number of people with atrial fibrillation, the rate of pacemaker implantation is expected to increase to treat heart diseases.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global active implantable medical devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the active implantable medical devices market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Boston Scientific Corporation, Medtronic Plc, MED-EL, Nurotron Biotechnology Co. Ltd., Abbott Laboratories, Cochlear Ltd, Sanova Holding AG, LivaNova Plc, Biotronik Inc., Osypka Medical among others.

Key Developments

• In June 2023, Medics invested £1.8 million for clinical trials with the aim of precisely targeting heart patients who need tiny defibrillators to be fitted under their skin with the aim of reducing deaths from sudden cardiac arrests.
• In June 2021, India Medtronic Private Limited launched Micra AV, a little, a fully self-contained pacemaker that uses a minimally invasive method to provide sophisticated pacing technology to those with atrioventricular (AV) block.

Why Purchase the Report?

• To visualize the global active implantable medical devices market segmentation based on device type, application, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of active implantable medical devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global active implantable medical devices market report would provide approximately 61 tables, 62 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Device Type
• 3.2. Snippet by Application
• 3.3. Snippet by End Users
• 3.4. Snippet by Region

4. Market Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing device launches
    • 4.1.1.2.
  • 4.1.2. Restraints
    • 4.1.2.1. Complications related to implantable pacemakers
    • 4.1.2.2.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Device Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 7.1.2. Market Attractiveness Index, By Device Type
• 7.2. Implantable Cardioverter Defibrillators*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Transvenous Implantable Cardioverter Defibrillators
    • 7.2.3.1. Biventricular Implantable Cardioverter Defibrillators
    • 7.2.3.2. Dual-Chamber Implantable Cardioverter Defibrillators
    • 7.2.3.3. Single-Chamber Implantable Cardioverter Defibrillators
  • 7.2.4. Subcutaneous Implantable Cardioverter Defibrillators
• 7.3. Implantable Cardiac Pacemakers
• 7.4. Ventricular Assist Devices
• 7.5. Neurostimulators
• 7.6. Implantable Hearing Devices
• 7.7. Implantable Heart Monitors
• 7.8. Implantable Glucose Monitors

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiovascular*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Neurology
• 8.4. Orthopedic
• 8.5. Others

9. By End Users

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.1.2. Market Attractiveness Index, By End Users
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ambulatory Surgical Centers
• 9.4. Cardiac Centers
• 9.5. Neuro Centers
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Boston Scientific Corporation
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Medtronic Plc
• 12.3. MED-EL
• 12.4. Nurotron Biotechnology Co. Ltd.
• 12.5. Abbott Laboratories
• 12.6. Cochlear Ltd
• 12.7. Sanova Holding AG
• 12.8. LivaNova Plc
• 12.9. Biotronik Inc.
• 12.10. Osypka Medical

LIST NOT EXHAUSTIVE.

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us